NEWS
Aug 12, 2026

SSRP Institute Welcomes IntellxxDNA as New Trusted Partner

PARTNER ANNOUNCEMENT

WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP's mission to advance science-first, education-driven clinical collaboration.

IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using curated SNP interaction analysis supported by peer-reviewed literature, their reports help identify additive risk patterns across neurological, metabolic, immune, and cardiometabolic pathways, while offering evidence-based intervention considerations related to lifestyle, nutrition, supplements, and medications.

“What excites me about IntellxxDNA and what they do is that it gives us a glimpse into each patient’s unique genetic makeup; a roadmap that helps us navigate their treatment and personalize the way we approach their care. What works for one patient might not work for another. Genomics is about connecting those dots and fully utilizing the available information to make each treatment fully individualized, leaving less to guesswork and more to what makes that patient uniquely them.” says Sanja Ryan, FNP and nominating SSRP Member. 

For SSRP Members, IntellxxDNA offers a practical way to integrate genomics into everyday clinical strategy without the time burden or complexity typically associated with genetic interpretation. Their clinician-only reporting system organizes relevant findings into clear, referenced summaries and highlights gene-to-gene and gene-environment interactions that influence common chronic conditions such as cognitive decline, mood disorders, cardiometabolic dysfunction, and neurodevelopmental challenges. Providers can access IntellxxDNA through a licensed clinician account, which includes training resources, sampler reports, and case-based education designed to support confident implementation in practice.

Carol Bilich, CEO of IntellxxDNA, said: "What is right for one patient, whether a peptide, supplement, medication, dietary strategy, or lifestyle change, may not be right for another. Genomics can help reveal why. SSRP and IntellxxDNA share a commitment to translating science into thoughtful, personalized clinical care and helping clinicians understand more of the individual patient. We are proud to be named a Trusted Partner and to support clinicians in making more informed, precise decisions."

Through these partnerships, the SSRP aims to support Members by connecting them with vetted resources that complement training, protocol development, and implementation in practice.

For more information and to view the IntellxxDNA Partner Page, visit:  SSRP IntellxxDNA Partner Page


About the SSRP Institute

The SSRP Institute is an education-focused organization dedicated to advancing cellular medicine through evidence-based training, professional collaboration, and clinically relevant research. SSRP supports providers worldwide through certifications, events, and ongoing educational programming designed to improve patient outcomes and elevate the standard of care.

The SSRP Trusted Partner Network is invitation-only and based on real-world clinical relevance, thoughtful nomination, and alignment with SSRP’s educational principles. Partners are integrated through a structured process designed to foster collaboration, support clinician education, and strengthen the implementation of cellular medicine practices.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
VIDEO
Cellular Medicine Mondays
Aug 31, 2026
Ep. 103 - Liposomal Peptides
Preview Only
Dissecting Protocols – Episode 103

Liposomal Peptides

Dr. Seeds takes a closer look at liposomal peptides, including Epitalon, BPC-157, TB4, KPV, and GHK-Cu, and examines the claims around sourcing, stability, absorption, bioavailability, injection fatigue, and whether these formulations can truly compare to injectable peptides.

Preview Only — Become a member for full access
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
BREAKING NEWS August 26, 2026 – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 24, 2026
Ep. 102 - Office Hours: PWC26 Virtual Summit Part 4
Preview Only
Office Hours PWC26 Virtual Summit Part 4 – Episode 102

Office Hours PWC26 Virtual Summit Part 4- Episode 102

  1. Compounded topical creams and GHK-Cu with microneedling (0:59)
  2. Detoxing before using copper (12:09)
  3. Patient onboarding process (12:54)
  4. Zinc and iron supplementation with GHK-Cu (23:41)
  5. Loss of taste after COVID (25:55)
  6. 3D CT scans for root canals (27:03)
  7. Oral bacteria swabs and GLP-1 effectiveness (28:00)
  8. Endocannabinoid system (29:07)
  9. GHK-Cu efficacy on wound beds (32:05)

Preview Only — Become a member for full access
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the molecule into the body, […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Aug 17, 2026
Ep. 101 - Office Hours: PWC26 Virtual Summit Part 3
Preview Only
Office Hours PWC26 Virtual Summit Part 3 – Episode 101

Office Hours PWC26 Virtual Summit Part 3 – Episode 101

1. Mitochondrial peptides (1:07)
2. MOTS-c cycle (3:50)
3. Injury site specific injection (9:25)
4. BPC-157 dosing (15:18)
5. Trusted labs (20:56)
6. What “redox” means (25:48)
7. Patient with cervical fusion, pain, and decreased range of motion (31:36)
8. Lipedema (37:03)
9. SS-31 and MOTS-c (37:52)
10. NanoVI device (44:49)
11. NAD (48:13)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Aug 10, 2026
Ep. 100 - Office Hours: PWC26 Virtual Summit Part 2
Preview Only
Office Hours PWC26 Virtual Summit Part 2 – Episode 100

Office Hours PWC26 Virtual Summit Part 2 – Episode 100

  1. Evaluating terrain of the patient (1:43)
  2. SS31 peptide in practice (8:50)
  3. Phenotyping the right patient for GLP-1 therapy (11:18)

 

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE
VIDEO
Cellular Medicine Mondays
Aug 3, 2026
Ep. 099 - Office Hours: PWC26 Virtual Summit Part 1
Preview Only
Office Hours: PWC26 Virtual Summit Part 1 – Episode 099

Office Hours: PWC26 Virtual Summit Part 1 – Episode 099

This special edition of Office Hours features questions submitted during the Peptide World Congress Virtual Summit on July 10 and 11. Dr. Seeds and Dr. Newman address:

  1. GLOW Stack, MOTS c, and Thyroid Function (0:50)
  2. Should the GLOW Stack Be Separated? (3:31)
  3. Peptides in Transplant Medicine (8:02)
  4. Biomarker Monitoring (13:21)
  5. Peptides in Acute and Long Term Stroke Recovery (17:37)
  6. Autoimmunity and the GI Tract (23:00)
  7. Cancer Concerns Related to Hormones and Angiogenesis (26:49)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Jul 27, 2026
Ep. 098 - Pentosan Polysulfate: Dosing, Safety, and Monitoring
Preview Only
Dissecting Protocols – Episode 098

Pentosan Polysulfate: Dosing, Safety, and Monitoring

Dr. Seeds examines the subcutaneous use of pentosan polysulfate, addressing concerns about injection site scarring and ocular safety. He discusses dosing, site rotation, cumulative exposure, retinal screening, and strategies for responsible, individualized treatment.(Question Link)

Preview Only — Become a member for full access
SSRP Institute Jul 24, 2026
PCAC Meeting Vote Summary
BREAKING NEWS JULY 24, 2026 – The Pharmacy Compounding Advisory Committee (PCAC) has completed its July session, voting on several peptide bulk drug substances for potential inclusion on the FDA’s 503A Bulks List.Recommended FOR inclusion: (Yes-No)• BPC-157 (8–6)• KPV (8–6)• TB-500 (8–6)• MOTS-c (7–5)• Epitalon (7–4)• Semax (8–5)Recommended AGAINST inclusion: (Yes-No)• DSIP (6–7) What happens […]
READ NEWS

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.